全身应用益生菌辅助牙周治疗的临床、微生物和免疫效果:随机对照试验研究方案
本随机对照试验旨在评估益生菌单独或联合甲硝唑加阿莫西林作为洁治和根面平整(SRP)辅助治疗牙周炎的临床、微生物和免疫效果。受试者随机分为SRP alone、益生菌、MTZ+AMX、益生菌+MTZ+AMX四组,随访12个月,检测龈下菌斑40种细菌和17种细胞因子/趋化因子。
要点
- 益生菌作为SRP辅助治疗牙周炎的临床、微生物和免疫效果尚待本RCT验证。
- MTZ+AMX联合SRP对广泛性III/IV期牙周炎是有效方案。
- 主要临床终点为1年时PD≥5mm位点≤4个的受试者比例。
研究设计与样本
- 随机对照试验,受试者为牙周炎患者,随机分配至SRP alone、益生菌、MTZ+AMX或益生菌+MTZ+AMX四组。
- 益生菌组每日2粒含片共90天;MTZ 400mg和AMX 500mg每日三次共14天。
- 随访至治疗后12个月,基线及3、6、12个月各采集9份龈下菌斑样本。
关键数值与推荐
- 临床治疗终点定义为1年时PD≥5mm的位点≤4个。
- 细菌检测采用checkerboard DNA-DNA杂交分析40种细菌。
- 免疫检测采用多重荧光珠基免疫分析17种细胞因子/趋化因子。
- 统计显著性设定为5%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The association of scaling and root planing (SRP) with systemic metronidazole (MTZ) plus amoxicillin (AMX) has shown to be an effective treatment protocol, particularly for periodontitis stages III and IV, generalized. More recently, probiotics have also been suggested as a promising adjunctive treatment for periodontal diseases due to their antimicrobial and anti-inflammatory properties. Therefore, the aim of this randomized clinical trial (RCT) is to evaluate the clinical, microbiological, and immunological effects of probiotics as adjuncts to SRP alone or with MTZ+AMX in the treatment of periodontitis. METHODS: Subjects with periodontitis are being randomly assigned to receive (i) SRP alone, or with (ii) two probiotic lozenges/day for 90 days (Prob), (iii) MTZ (400 mg) and AMX (500 mg) thrice a day (TID) for 14 days (MTZ+AMX), or (iv) Prob and MTZ+AMX. Subjects are being monitored for up to 12 months post-treatment. Nine subgingival plaque samples per patient are being collected at baseline and at 3, 6, and 12 months post-therapy and analyzed by checkerboard DNA-DNA hybridization for 40 bacterial species. Peripheral blood and gingival crevicular fluid (GCF) of four randomly selected periodontal sites will be analyzed by means of a multiplex fluorescent bead-based immunoassay for 17 cyto/chemokines. STATISTICAL ANALYSES: The significance of differences in each group (over the course of the study) will be sought using repeated measures ANOVA or Friedman tests and among groups (at each time point) using either ANOVA/ANCOVA or Kruskal-Wallis tests, depending on normality of the data. The chi-square test will be used to compare differences in the frequency of subjects achieving the clinical endpoint for treatment (≤ 4 sites with PD ≥ 5 mm) at 1 year and of self-perceived adverse effects. A stepwise forward logistic regression analysis will be performed in order to investigate the impact of different predictor variables on the percentage of patients achieving the clinical endpoint for treatment. The Number Needed to Treat (NNT) with different treatment protocols will be also calculated. Statistical significance will be set at 5%. TRIAL REGISTRATION: ClinicalTrials.gov NCT03733379. Registered on November 7, 2018.
引用
- Retamal-Valdes B, Teughels W, Oliveira LM, et al. Clinical, microbiological, and immunological effects of systemic probiotics in periodontal treatment: study protocol for a randomized controlled trial. Trials. 2021. PMID: 33858486. doi:10.1186/s13063-021-05246-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。